23-Valent Pneumococcal Polysaccharide Vaccine Market Size, Competitive Landscape and Regional Analysis, Forecast to 2031

According to our (Global Info Research) latest study, the global 23-Valent Pneumococcal Polysaccharide Vaccine market size was valued at US$ 1140 million in 2023 and is forecast to a readjusted size of USD 2212 million by 2030 with a CAGR of 10.0% during review period.

23-Valent Pneumococcal Polysaccharide Vaccine is a kind of vaccine used to prevent infection caused by pneumococcal bacteria. 23-Valent Pneumococcal Polysaccharide Vaccine contains 23 of the most common types of pneumococcal bacteria. 23-Valent Pneumococcal Polysaccharide Vaccine is for use only in adults and children who are at least 2 years old. For children younger than 2 years old, another vaccine called Prevnar (pneumococcal conjugate vaccine [PCV] 7-valent) is used, usually given between the ages of 2 months and 15 months.

Market Drivers:

The 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) market is driven by the increasing prevalence of pneumococcal infections, particularly among high-risk populations such as the elderly, children, and immunocompromised individuals. Governments and health organizations worldwide are promoting vaccination programs to reduce the burden of pneumococcal diseases, which has significantly boosted market growth. Additionally, rising awareness about the importance of preventive healthcare and advancements in vaccine manufacturing technologies contribute to the increased adoption of PPSV23 vaccines.

Market Challenges:

However, the market faces challenges such as the high cost of vaccination, which limits accessibility in low- and middle-income countries. Moreover, the competition from newer pneumococcal conjugate vaccines (PCVs), which offer broader coverage and are preferred for pediatric use, poses a threat to PPSV23's market share. Another concern is vaccine hesitancy and misinformation, which can hinder immunization efforts and impact the overall market growth.

Merck is the largest manufacturers of 23-Valent pneumococcal polysaccharide vaccine in the world, has a share about 78%. Other players include Sinovac, Kangtai Bio, CDIBP, Walvax, etc. United States is dominating the global 23-Valent pneumococcal polysaccharide vaccine market, has a share nearly 78% in terms of production. The largest market is United States, holds a share about 48%, followed by China and Europe, with around 25% and 22% market share respectively.

This report is a detailed and comprehensive analysis for global 23-Valent Pneumococcal Polysaccharide Vaccine market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.


"23-Valent Pneumococcal Polysaccharide Vaccine" 2025 Breakdown, Data Source, Secondary Sources, Primary Sources, Research Report delivers leading competitors strategic analysis, with micro and macro-economic factors, market trends, future growth scenarios, with pricing analysis. This report provides a holistic overview on Market Current Situations, Key Collaborations, Merger & Acquisitions along with Trending Innovations and New Business Development Policies. A detailed professional report focusing on primary and secondary growth drivers, regional segments, growth share, and geographical analysis of top key players. 23-Valent Pneumococcal Polysaccharide Vaccine trend analysis with historical data, estimates to 2025 and Compound Annual Growth Rate (CAGR) forecast to 2031.

Top Key Players Covered in Market Report 2025-2031:Merck、Sinovac、Kangtai Bio、CDIBP、Walvax

Request for a Sample PDF of 23-Valent Pneumococcal Polysaccharide Vaccine Report
https://www.globalinforesearch.com/reports/1684744/23-valent-pneumococcal-polysaccharide-vaccine

Short Description of the 23-Valent Pneumococcal Polysaccharide Vaccine 2025-2031:
Market Overview of Global 23-Valent Pneumococcal Polysaccharide Vaccine: According to our latest research, the global 23-Valent Pneumococcal Polysaccharide Vaccine looks promising in the next 6 years. As of 2025, the global 23-Valent Pneumococcal Polysaccharide Vaccine was estimated at USD Million, and it’s anticipated to reach USD Million in 2031, with a CAGR during the forecast years. This report covers a research time span from 2020 to 2031, and presents a deep and comprehensive analysis of the global 23-Valent Pneumococcal Polysaccharide Vaccine, with a systematical description of the status quo and trends of the whole market, a close look into the competitive landscape of the major players, and a detailed elaboration on segment markets by type, by application and by region.

Global and Regional Analysis:
    North America (United States, Canada and Mexico)

    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

    South America (Brazil, Argentina, Colombia, and Rest of South America)

    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

Market Segmentation
23-Valent Pneumococcal Polysaccharide Vaccine report provides an exhaustive 360-degree analysis, by utilizing both primary and secondary research techniques. The research gained comprehensive insights into current market dynamics, pricing trends, developments, supply-demand and evolving consumer behaviors.

On the basis of product type, this report displays the production, revenue, price, market
Single Dose Vial、Pre-filled Syringe

On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each
For Children (Over 2 Years Old)、For Adult

Inquire or Share Your Questions If Any before Purchasing This Report
https://www.globalinforesearch.com/contact-us

Our method for estimating market size is holistic and multifaceted. We assess vital industry trends, regulatory landscapes, and segment-specific dynamics, evaluating their potential influence on demand projections. Key macroeconomic factors, including price fluctuations, demographic shifts, and changes in demand patterns, are integrated into our calculations. To discover market value, we not only delve deep into the profiles of prominent players and their global market shares but also rely on our frequently updated internal database, enriched with insights and announcements from pivotal market stakeholders.

Some of the Key Questions Answered in this Report:

1. What is the 23-Valent Pneumococcal Polysaccharide Vaccine size at the regional and country level

2. What are the key drivers, restraints, opportunities, and challenges of the 23-Valent Pneumococcal Polysaccharide Vaccine, and how they are expected to impact the market

3. What is the global (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa) sales value, production value, consumption value, import and export of 23-Valent Pneumococcal Polysaccharide Vaccine

4. Who are the global key manufacturers of the 23-Valent Pneumococcal Polysaccharide Vaccine? How is their operating situation (capacity, production, sales, price, cost, gross, and revenue)

5. What are the 23-Valent Pneumococcal Polysaccharide Vaccine opportunities and threats faced by the vendors in the 23-Valent Pneumococcal Polysaccharide Vaccine?

6. Which application/end-user or product type may seek incremental growth prospects? What is the market share of each type and application?

7. What focused approach and constraints are holding the 23-Valent Pneumococcal Polysaccharide Vaccine?

8. What are the different sales, marketing, and distribution channels in the global industry?

9. What are the key market trends impacting the growth of the 23-Valent Pneumococcal Polysaccharide Vaccine?

10. Economic Impact on the 23-Valent Pneumococcal Polysaccharide Vaccine and development trend of the 23-Valent Pneumococcal Polysaccharide Vaccine

11. What are the 23-Valent Pneumococcal Polysaccharide Vaccine opportunities, market risk, and market overview of the 23-Valent Pneumococcal Polysaccharide Vaccine

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Hydrogen Bromide product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of Hydrogen Bromide, with price, sales, revenue and global market share of Hydrogen Bromide from 2020 to 2025.

Chapter 3, the Hydrogen Bromide competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Hydrogen Bromide breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2020 to 2031.

Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2020 to 2031.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2020 to 2024.and 23-Valent Pneumococcal Polysaccharide Vaccine forecast, by regions, type and application, with sales and revenue, from 2026 to 2031.

Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.

Chapter 13, the key raw materials and key suppliers, and industry chain of Hydrogen Bromide.

Chapter 14 and 15, to describe Hydrogen Bromide sales channel, distributors, customers, research findings and conclusion.

About Us:
GlobaI Info Research
Web: https://www.globalinforesearch.com
CN: 0086-176 6505 2062
HK: 00852-58030175
US: 001-347 966 1888
Email: report@globalinforesearch.com

Global Info Research is a company that digs deep into global industry information to support enterprises with market strategies and in-depth market development analysis reports. We provides market information consulting services in the global region to support enterprise strategic planning and official information reporting, and focuses on customized research, management consulting, IPO consulting, industry chain research, database and top industry services. At the same time, Global Info Research is also a report publisher, a customer and an interest-based suppliers, and is trusted by more than 30,000 companies around the world. We will always carry out all aspects of our business with excellent expertise and experience.